Overall, the reviewers wrote, most IBD therapies “appear safe and effective when used in chronic kidney disease, including on ...

The Swedish drugmaker has come up short in its effort to push imlifidase into treatment of the autoimmune condition ...

Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a medication ...

A groundbreaking discovery offers hope for reversing kidney damage, challenging the notion that it's irreversible.

Dr Dana Rizk is Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB) and a VOYXACT VISIONARY Study Investigator and Co-Chair of the Steering Committee.

This year’s most-read articles on CKD highlighted research and insights on drug approvals, guidelines, and value-based care.

PKD is mainly caused by mutations in the PKD1 and PKD2 genes, affecting polycystin proteins. Disrupted signaling pathways, like cAMP and vasopressin, are major drivers of cyst growth. Tolvaptan is ...

Post hoc trial findings support aprocitentan’s potential cardiovascular and kidney-protective effects in patients with chronic kidney disease (CKD) with resistant hypertension.

Researchers at the Perelman School of Medicine identified over 1,000 genes that could serve as potential treatment targets for kidney disease in a newly published study. The study marks the most ...

Treatments commonly used to prevent acute kidney failure and its complications arising from common angiography procedures make no difference to health outcomes, a major new study has found. A team of ...

In a new study, researchers examined the Renal Activity Index for Lupus (RAIL) diagnostic tool to assess its success for ...